Pegfilgrastim biosimilar - Coherus BioSciences

Drug Profile

Pegfilgrastim biosimilar - Coherus BioSciences

Alternative Names: CHS-1701

Latest Information Update: 01 Dec 2016

Price : $50

At a glance

  • Originator Coherus Biosciences
  • Developer Coherus BioSciences
  • Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Neutropenia

Most Recent Events

  • 29 Nov 2016 Preregistration for Neutropenia in European Union (SC)
  • 29 Nov 2016 Pegfilgrastim biosimilar - Coherus BioSciences is available for licensing in the European Union as of 29 Nov 2016
  • 09 Nov 2016 Coherus BioSciences announces intention to submit MAA in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top